home / stock / pbla / pbla news

PBLA News and Press, Panbela Therapeutics Inc Com From 01/26/23

Stock Information
Company Name: Panbela Therapeutics Inc Com
Stock Symbol: PBLA
Market: NASDAQ
Website: panbela.com
Menu
PBLA PBLA Quote PBLA Short PBLA News PBLA Articles PBLA Message Board
Get PBLA Alerts

News, Short Squeeze, Breakout and More Instantly...
PBLA - Panbela Announces Pricing of Approximately $15 Million Public Offering

MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA) , (“Panbela” or the “Company”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced t...
PBLA - Panbela's therapy for pancreatic cancer gets orphan drug status in EU

The European Commission (EC) granted orphan drug designation to Panbela Therapeutics' ( NASDAQ: PBLA ) ivospemin to treat a type of pancreatic cancer. The EC adopted the positive opinion issued by a panel of the European Medicines Agency (EMA) to designate the s...

PBLA - Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for Or...

PBLA - Panbela Therapeutics to execute 1-for-40 reverse stock split

Panbela Therapeutics ( NASDAQ: PBLA ) is set to execute a 1-for-40 reverse split of its common stock to aid compliance with Nasdaq's continued listing requirements. The common stock will trade on a post-split basis at the beginning of trading on January 13, 2023 under the existing...
PBLA - Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) --  -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announce...

PBLA - Panbela surges 19% on starting phase II trial of CPP-1X-T for type I diabetes

Panbela Therapeutics ( NASDAQ: PBLA ) is trading ~19% higher after it begun a Phase II study to test CPP-1X-T (Eflornithine tablets) for type 1 diabetes, in collaboration with Indiana University School of Medicine. The study will test patients with recent onset type ...

PBLA - Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it has commenced a Phase II double-blind, randomized st...
PBLA - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are acquisition deals, clinical trial data, a failed...

PBLA - Panbela stock surges 20% as EMA panel backs granting orphan drug status to cancer drug

A committee of the European Medicines Agency (EMA) issued a positive opinion on Panbela Therapeutics' ( NASDAQ: PBLA ) application for orphan designation for ivospemin (SBP-101) to treat a type of pancreatic cancer. The EMA's Committee for Orphan Medicinal Prod...

PBLA - Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pa nbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the European Medicines Agency (EMA) Committee for ...
Previous 10 Next 10